RT期刊文章SR电子T1为神经细胞干预条件下摩根富林明神经学神经学乔FD Lippincott Williams &威尔金斯SP 288 OP 293 10.1212/01. wn首页l.0000316436.13659.80 VO 71是4 A1 D.J.H. Mathews A1 j .苏格曼A1 h·博克A1 d·m·布拉斯A1 j . t . Coyle A1 p Duggan A1 j·芬克尔A1 h . t . Greely A1。希利斯A1。废话A1 r·约翰逊A1 m·约翰斯顿A1 j . Kahn A1 d·克尔A1 j . Kurtzberg A1 s·m·廖A1 j·w·麦克唐纳A1 g . McKhann称A1 K。b . Nelson A1 m . Rao A1。Regenberg A1。•西格尔(george w . bush) A1 K。史密斯A1 d你A1 h .歌曲A1。Vescovi A1 W。年轻的A1 j . d . Gearhart A1 r法登年2008 UL http://n.neurology首页.org/content/71/4/288.abstract AB背景:尝试翻译基本干细胞治疗神经系统疾病和损伤的研究正在顺利进行。其中一个治疗的临床试验批准和进步在美国,和额外的建议进行审查,我们必须开始处理等提出的伦理问题及早进入人体临床试验为神经细胞干预条件。 Methods: An interdisciplinary working group composed of experts in neuroscience, cell biology, bioethics, law, and transplantation, along with leading disease researchers, was convened twice over 2 years to identify and deliberate on the scientific and ethical issues raised by the transition from preclinical to clinical research of cell-based interventions for neurologic conditions. Results: While the relevant ethical issues are in many respects standard challenges of human subjects research, they are heightened in complexity by the novelty of the science, the focus on the CNS, and the political climate in which the science is proceeding. Conclusions: Distinctive challenges confronting US scientists, administrators, institutional review boards, stem cell research oversight committees, and others who will need to make decisions about work involving stem cells and their derivatives and evaluate the ethics of early human trials include evaluating the risks, safety, and benefits of these trials, determining and evaluating cell line provenance, and determining inclusion criteria, informed consent, and the ethics of conducting early human trials in the public spotlight. Further study and deliberation by stakeholders is required to move toward professional and institutional policies and practices governing this research. CBI-NCs=cell-based interventions for neurologic conditions; ESCROs=embryonic stem cell research oversight committees; FDA=Food and Drug Administration; hESCs=human embryonic stem cells; IND=Investigational New Drug; IRBs=institutional review boards.